<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02447692</url>
  </required_header>
  <id_info>
    <org_study_id>IPR-327433, ISR-2014-10481</org_study_id>
    <nct_id>NCT02447692</nct_id>
  </id_info>
  <brief_title>Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The PROMIZING Study</brief_title>
  <acronym>PROMIZING</acronym>
  <official_title>Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The PROMIZING Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Critical Care Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For adult patients with acute respiratory failure requiring invasive mechanical ventilation,&#xD;
      does a ventilation strategy using proportional assist ventilation with load-adjustable gain&#xD;
      factors (PAV+) result in a shorter duration of time spent on mechanical ventilation than a&#xD;
      ventilation strategy using pressure support ventilation (PSV)?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with acute respiratory failure require mechanical ventilation to help them breathe&#xD;
      until they recover from their acute illness. Although mechanical ventilation is necessary to&#xD;
      sustain life in such situations, it can induce weakness of the respiratory muscles which may&#xD;
      lead to prolonged dependence on the ventilator. Prolonged dependence on mechanical&#xD;
      ventilation is associated with increased mortality, morbidity and costs to the healthcare&#xD;
      system. Thus, a main goal of assisted mechanical ventilation is to reduce the patient's&#xD;
      respiratory distress while maintaining some respiratory muscle activity. To attain this goal,&#xD;
      the amount of ventilator assistance should theoretically be adjusted to target normal or&#xD;
      reasonable levels of respiratory effort.&#xD;
&#xD;
      Modes of Mechanical Ventilation:&#xD;
&#xD;
      Proportional assist ventilation with load-adjustable gain factors (PAV+) is a mode of&#xD;
      mechanical ventilation which delivers assistance to breathe in proportion to the patient's&#xD;
      effort. The proportional assistance, called the gain, can be adjusted by the clinician to&#xD;
      maintain the patient's respiratory effort or workload within a reasonable range. This is the&#xD;
      only mode of ventilation which allows for measurement and targeting of a specific range of&#xD;
      respiratory muscle activity by the patient.&#xD;
&#xD;
      Pressure support ventilation (PSV) is a mode of ventilation which is considered the current&#xD;
      standard of care for assisting breathing of patients during the recovery phase of acute&#xD;
      respiratory failure. Several studies have shown short term advantages of PAV over PSV,&#xD;
      including improved patient-ventilator synchronization, improved adaptability to changes in&#xD;
      patient effort, and improved sleep quality.&#xD;
&#xD;
      Goal of this Randomized Controlled Trial:&#xD;
&#xD;
      To demonstrate that for patients with acute respiratory failure, ventilation with PAV+, being&#xD;
      more physiological, will result in a shorter duration of time spent on mechanical ventilation&#xD;
      than ventilation with PSV.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from randomization to successful liberation from invasive mechanical ventilation.</measure>
    <time_frame>up to 90 days</time_frame>
    <description>&quot;Successful liberation&quot; is defined as removal of the endotracheal tube AND remaining alive with no need for reintubation/reinstitution of invasive mechanical ventilation for 7 days post extubation, or until successful ICU discharge, or until live hospital discharge, whichever comes first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days at 14, 21 and 28 days post randomization</measure>
    <time_frame>14, 21 and 28 days post randomization</time_frame>
    <description>&quot;Ventilator-free days&quot; (VFDs) are defined as the number of days alive and free of INVASIVE ventilation post SUCCESSFUL EXTUBATION or post successful termination of invasive mechanical ventilation (MV) from time of randomization to day 21 post randomization. &quot;Successful extubation&quot; is defined as removal of the endotracheal tube AND remaining alive with no need for reintubation/reinstitution of invasive mechanical ventilation for 7 days post extubation, or until successful ICU discharge, or until live hospital discharge, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from randomization to live ICU discharge (up to day 90)</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Patients will remain in the study and will continue on the assigned ventilation strategy until: successful extubation, successful ICU discharge, live hospital discharge, death, or 90 days post randomization, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from randomization to live hospital discharge (up to day 90)</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Patients will remain in the study and will continue on the assigned ventilation strategy until: successful extubation, successful ICU discharge, live hospital discharge, death, or 90 days post randomization, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Measured as ICU mortality; hospital mortality; 14, 21, 28, and 90 day mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weaning Progress</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Measured as time from randomization to: first SBT; first successful SBT; first extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weaning Difficulties</measure>
    <time_frame>90 days</time_frame>
    <description>Measured as the number of patients failing first SBT or first extubation attempt and requiring up to 7 days to extubate (difficult weaning group/group 2); failing first SBT or first extubation attempt and requiring more than 7 days to extubate (prolonged weaning group/group 3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weaning Complications</measure>
    <time_frame>90 days</time_frame>
    <description>Measured as the number of patients: requiring non-invasive ventilation post-extubation; ventilated more than 7 days post randomization, ventilated more than 21 days from time of intubation (prolonged MV group); receiving tracheostomy post-randomization, requiring re-intubation (up to 7d after planned extubation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of modes</measure>
    <time_frame>90 days</time_frame>
    <description>Measured as number of patients ever requiring A/C mode post randomization; number of patient-days requiring A/C mode post randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative dose of narcotics (converted to morphine equivalents); benzodiazepines (converted to midazolam equivalents); propofol, and dexmedetomidine</measure>
    <time_frame>90 days</time_frame>
    <description>These are measures of sedation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients and number of patient-days receiving any antipsychotic medication</measure>
    <time_frame>28 days</time_frame>
    <description>This is a surrogate measure of delirium</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Subgroup analyses based on: (a) duration of MV prior to randomization greater than 5 days</measure>
    <time_frame>90 days</time_frame>
    <description>Identifies a subgroup of patients at time of randomization who are at risk for prolonged weaning</description>
  </other_outcome>
  <other_outcome>
    <measure>Subgroup analyses based on (b) failing an SBT prior to randomization</measure>
    <time_frame>90 days</time_frame>
    <description>Identifies a subgroup of patients at time of randomization classified as difficult weaning vs. failed CPAP 0 trial vs. failed weaning criteria prior to randomization</description>
  </other_outcome>
  <other_outcome>
    <measure>Subgroup analyses based on (c) failed extubation prior to randomization</measure>
    <time_frame>90 days</time_frame>
    <description>Identifies a subgroup of patients at time of randomization classified as having &quot;difficult weaning&quot;.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subgroup analyses based on (d) mild vs. moderate vs. severe frailty</measure>
    <time_frame>90 days</time_frame>
    <description>Differentiates between severely frail and less frail</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">558</enrollment>
  <condition>Critically Ill</condition>
  <condition>Acute Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>PSV ventilation strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control is the standard of care PSV ventilation strategy, designed to adjust the level of support according to usual clinical parameters.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAV+ ventilation strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The intervention is a PAV+ ventilation strategy, designed to adjust the level of support (gain) to target a predefined range of respiratory muscle pressure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PSV ventilation strategy</intervention_name>
    <description>An algorithm for adjusting the level of pressure support according to usual clinical parameters; patients not tolerating PSV will be switched to Assist/Control mode according to predefined criteria</description>
    <arm_group_label>PSV ventilation strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PAV+ ventilation strategy</intervention_name>
    <description>An algorithm for adjusting the level of support (gain) to maintain a predefined range of respiratory muscle pressure; patients not tolerating PAV+ (Puritan Bennett™ 840 or 980 ventilator) will be switched to Assist/Control mode according to predefined criteria</description>
    <arm_group_label>PAV+ ventilation strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        A staged enrolment process will be used to identify patients eligible to be enrolled and&#xD;
        randomized in the study. At each stage of the enrolment process, a patient must meet&#xD;
        inclusion criteria and not meet exclusion criteria in order to pass. To progress to the&#xD;
        next stage, patients must continue to pass criteria from the prior stages. After enrolment,&#xD;
        there are also specific tests to perform (with pass/fail criteria) to determine eligibility&#xD;
        to be randomized.&#xD;
&#xD;
        A. SCREENING INCLUSION CRITERIA:&#xD;
&#xD;
          -  A1. Age 18 years or older&#xD;
&#xD;
          -  A2. Intubated and receiving any mode of invasive mechanical ventilation ≥ 24 hours&#xD;
&#xD;
        A. SCREENING EXCLUSION CRITERIA:&#xD;
&#xD;
          -  A3. Anticipating withdrawal of life support and/or shift to palliation as the goal of&#xD;
             care&#xD;
&#xD;
          -  A4. Severe central neurologic disorder (eg. Hemorrhage, stroke, tumour) causing&#xD;
             elevated intracranial pressure, or impaired control of breathing, or requiring&#xD;
             specific ventilator adjustments (i.e. To attain specific CO2 target) or requiring&#xD;
             neurosurgical intervention&#xD;
&#xD;
          -  A5. Known or suspected severe or progressive neuromuscular disorder likely to result&#xD;
             in prolonged or chronic ventilator dependence (eg. Guillain-Barré syndrome, Myasthenia&#xD;
             Gravis, ALS, MS, high spinal cord injury, kyphoscoliosis or other restrictive&#xD;
             disorder) (Note that obesity hypoventilation syndrome that may be managed with&#xD;
             nocturnal non-invasive ventilation is NOT an exclusion under A5)&#xD;
&#xD;
          -  A6. Severe COPD: Baseline daytime hypercapnea (pCO2&gt; 50 mmHg) OR GOLD 4 airflow&#xD;
             limitation (FEV1&lt;30% predicted) OR MRC class 4 symptoms (&quot;I am too breathless to leave&#xD;
             the house&quot; OR &quot;I am breathless when dressing&quot;)&#xD;
&#xD;
          -  A7. Broncho-pleural fistula&#xD;
&#xD;
          -  A8. Tracheostomy present at ICU admission for the purpose of chronic or prolonged&#xD;
             mechanical ventilation (&gt;21 days). (Note that a patient who was endotracheally&#xD;
             intubated for acute respiratory failure and received a tracheostomy during their ICU&#xD;
             admission, prior to enrolment, is not excluded under A8).&#xD;
&#xD;
          -  A9. Current enrolment in a confounding study, as assessed by the steering committee&#xD;
&#xD;
          -  A10. Previous randomization in the PROMIZING Study&#xD;
&#xD;
          -  A11. Severe, end-stage, irreversible respiratory or cardiac disease (e.g. interstitial&#xD;
             lung disease, pulmonary fibrosis, cardiomyopathy, valvulopathy) likely to result in&#xD;
             prolonged or chronic ventilator dependence /unlikely to wean from mechanical&#xD;
             ventilation [Note: patients who are candidates for intervention to treat the&#xD;
             underlying respiratory/cardiac disease (e.g. lung transplant, heart transplant,&#xD;
             cardiac surgery) may be re-evaluated once intervention is complete and they no longer&#xD;
             meet criteria A11.]&#xD;
&#xD;
        B. ENROLMENT INCLUSION CRITERIA:&#xD;
&#xD;
          -  B1. Ability or potential ability to trigger ventilator breaths (i.e. not receiving&#xD;
             neuromuscular blockade).&#xD;
&#xD;
          -  B2. On Assist/Control volume-cycled ventilation: Technically satisfactory plateau&#xD;
             pressure ≤ 30 cm H2O (see Operations Manual) OR On Assist/Control pressure-controlled&#xD;
             ventilation or similar mode: Pressure control plus PEEP ≤ 30 cm H2O OR On Pressure&#xD;
             Support ventilation: Pressure support plus PEEP ≤ 30 cm H2O OR On Proportional Assist&#xD;
             ventilation: PAV gain &lt;85%&#xD;
&#xD;
          -  B3. PaO2 ≥ 60 mmHg or SpO2 ≥ 90% on FiO2 ≤ 0.60 and PEEP ≤ 15 cm H2O&#xD;
&#xD;
          -  B4. Metabolic disorders corrected: pH ≥7.32&#xD;
&#xD;
          -  B5. Stable hemodynamic status: stable or decreasing doses of vasopressors for ≥6 hours&#xD;
&#xD;
          -  B6. Anticipate ongoing need for ventilation &gt;24 hours&#xD;
&#xD;
        B. ENROLMENT EXCLUSION CRITERIA:&#xD;
&#xD;
          -  B7. Extubated&#xD;
&#xD;
          -  B8. Died&#xD;
&#xD;
          -  B9. Patient has met enrolment inclusion criteria B1-B5 AND has tolerated pressure&#xD;
             support of 0-20 cm H2O or proportional assist ventilation of 0-85% for ≥24 consecutive&#xD;
             hours (including time on CPAP, t-piece, or tracheostomy mask). (Note (1): that it is&#xD;
             acceptable to include a patient who has been tried on pressure support or proportional&#xD;
             assist ventilation but has required pressures &gt;20 cmH2O or assistance &gt;85% or has&#xD;
             required return to A/C ventilation within the 24 hour time window; Note (2): B9 does&#xD;
             not apply to patients on ECMO.)&#xD;
&#xD;
          -  B10. Patient transferred to a non-participating centre&#xD;
&#xD;
        B. ENROLMENT DEFERRAL CRITERIA:&#xD;
&#xD;
          -  B11. Plan to extubate/discontinue mechanical ventilation within &lt;24 hours (Reassess&#xD;
             within 24 hours)&#xD;
&#xD;
          -  B12. Patient currently on ECMO (Reassess patient once off ECMO)&#xD;
&#xD;
          -  C9: Plan for surgery or complex procedure that will require full ventilation to be&#xD;
             done prior to attempting extubation (e.g. Procedure requiring neuromuscular blockade&#xD;
             and/or heavy sedation, such that patient would be apneic, or not be able to trigger&#xD;
             ventilator) (Reassess after surgery/procedure complete)&#xD;
&#xD;
        C. PRESSURE SUPPORT TRIAL INCLUSION CRITEIRA:&#xD;
&#xD;
          -  C2. Upon review of Screening and Enrolment criteria (A and B), the patient still&#xD;
             passes.&#xD;
&#xD;
          -  C3. Treating physician has provided verbal consent to proceed with standardized tests&#xD;
             and randomization if eligibility criteria are met.&#xD;
&#xD;
        C. PRESSURE SUPPORT TRIAL DEFERRAL CRITERIA:&#xD;
&#xD;
          -  C6. High dose vasopressor requirements (i.e. epinephrine or norepinephrine &gt;0.5&#xD;
             ug/kg/min or equivalent) OR patient requiring an increase in dose of vasopressor&#xD;
             within 6 hrs&#xD;
&#xD;
          -  C7. Active cardiac ischemia (dynamic ST changes on monitor or ECG within 6 hours)&#xD;
&#xD;
          -  C8. Unstable arrhythmias (HR&gt;140 or &lt;50) with clinical signs of low cardiac output or&#xD;
             or SBP&lt;80 mmHg&#xD;
&#xD;
          -  C10. Receiving a &quot;strict lung protective&quot; ventilation strategy for ARDS (eg. Order on&#xD;
             chart to keep Vt ≤6 mL/kg PBW)&#xD;
&#xD;
        C. PRESSURE SUPPORT TRIAL EXCLUSION CRITERIA:&#xD;
&#xD;
        • C12. Treating physician has declined consent&#xD;
&#xD;
        D. WEANING CRITERIA:&#xD;
&#xD;
          -  D1. SpO2≥ 90% on FiO2 ≤0.40 and PEEP ≤8 cmH2O&#xD;
&#xD;
          -  D2. pH ≥7.32&#xD;
&#xD;
          -  D3. Vasopressor requirements no higher than norepinephrine 0.1 ug/kg/min or&#xD;
             equivalent.&#xD;
&#xD;
        In the final stage (E), patients will be considered eligible for randomization if the&#xD;
        following criteria are met.&#xD;
&#xD;
        E. RANDOMIZATION INCLUSION CRITERIA:&#xD;
&#xD;
          -  C1. Patient/SDM has provided consent OR Plan to obtain deferred consent as Patient&#xD;
             incapable and no SDM available to provide consent within the randomization window&#xD;
&#xD;
          -  E1. Upon review of Criteria A, B, and C, the patient still passes and the patient has&#xD;
             passed the PST.&#xD;
&#xD;
          -  E2. Does not meet Weaning Criteria OR Fails the ZERO CPAP Trial OR Fails the SBT&#xD;
&#xD;
        E. RANDOMIZATION EXCLUSION CRITERIA:&#xD;
&#xD;
          -  B9. Patient has met enrolment inclusion criteria B1-B5 AND has tolerated pressure&#xD;
             support of 0-20 cm H2O or proportional assist ventilation of 0-85% ≥24 consecutive&#xD;
             hours (including time on CPAP, t-piece, or tracheostomy mask). Note (1): It is&#xD;
             acceptable to include a patient who has been tried on pressure support or proportional&#xD;
             assist ventilation but has required pressures &gt;20 cmH2O or assistance &gt;85% or has&#xD;
             required return to A/C ventilation within the 24 hour time window; Note (2): B9 does&#xD;
             not apply to patients while on ECMO&#xD;
&#xD;
          -  C4. Patient/SDM has declined consent&#xD;
&#xD;
          -  C5. Patient incapable and no SDM available to provide consent (not applicable if plan&#xD;
             to obtain deferred consent)&#xD;
&#xD;
          -  E3. Passed SBT on t-piece, FiO2 0.40 for 30-120 minutes&#xD;
&#xD;
          -  E4. Approval withdrawn (by physician or patient/SDM)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen J Bosma</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Health Sciences Centre, London, Ontario, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurent Brochard</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, Toronto, Ontario, Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sorcha Mulligan</last_name>
    <phone>416-360-4000</phone>
    <phone_ext>77049</phone_ext>
    <email>Sorcha.Mulligan@unityhealth.to</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen J Bosma</last_name>
    <phone>519-663-3531</phone>
    <email>KarenJ.Bosma@lhsc.on.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Columbian Hospital</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre - University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K.J. Bosma</last_name>
      <phone>519-663-3531</phone>
      <email>karenj.bosma@lhsc.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Tracey Bentall</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>32546</phone_ext>
      <email>traceyc.bentall@lhsc.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Karen J. Bosma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Victoria Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Martin</last_name>
      <email>claudio.martin@lhsc.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Eileen Campbell</last_name>
      <email>Eileen.Campbell@lhsc.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Claudio Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Boyd</last_name>
      <email>Tracy.boyd@kingstonhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Stephanie Sibley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>North York General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phil Shin</last_name>
    </contact>
    <contact_backup>
      <email>Phil.Shin@nygh.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Phil Shin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Brochard</last_name>
      <email>brochardl@smh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Piraino</last_name>
      <email>pirainot@smh.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Karen Burns</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent Brochard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UHN- Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niall Ferguson</last_name>
      <email>Niall.Ferguson@uhn.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UHN- Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Niall Ferguson</last_name>
      <email>Niall.Ferguson@uhn.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital du Sacré-Cœur de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Shahin</last_name>
      <email>jason.shahin@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Josie Campisi</last_name>
      <email>josie.campisi@muhc.mcgill.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Jason Shahin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de cardiologie et de pneumologie de Quebec</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois Lellouche</last_name>
      <email>francois.lellouche@criucpq.ulaval.ca</email>
    </contact>
    <contact_backup>
      <last_name>Pierre-Alexandre Bouchard</last_name>
      <email>pierre-alexandre.bouchard@criucpq.ulaval.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Francois Lellouche</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire (CHU) de Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Mercat</last_name>
      <email>alain.mercat@univ-angers.fr</email>
    </contact>
    <contact_backup>
      <last_name>Laure Masson</last_name>
      <email>lamasson@chu-angers.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Alain Mercat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>QFW8+H5</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tommaso MARAFFI</last_name>
      <email>tommaso.maraffi@chicreteil.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor (Assistance Publique-Hôpitaux de Paris)</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Carteaux</last_name>
      <email>guillaume.carteaux@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Guillaume Carteaux</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire (CHU) de Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Dres</last_name>
      <email>martin.dres@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Alexandre Demoule</last_name>
      <email>alexandre.demoule@aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Dres</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre Demoule</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire (CHU) de Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaetan Beduneau</last_name>
      <email>gaetan.beduneau@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Gaetan Beduneau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Heraklion</name>
      <address>
        <city>Heraklion</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Katerina Vaporidi</last_name>
      <email>vaporidi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Katerina Vaporidi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Ferrara</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Savino Spadaro</last_name>
      <email>savinospadaro@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Carlo Alberto Volta</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Savino Spadaro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabetta Marangoni</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Giovanni Battista University Hospital</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vito Faneilli</last_name>
      <email>vito.fanelli@unito.it</email>
    </contact>
    <investigator>
      <last_name>Vito Fanelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Carlos Suarez Montero</last_name>
      <email>jsuarez@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Juan Carlos Suarez Montero</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jordi Mancebo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 8, 2015</study_first_submitted>
  <study_first_submitted_qc>May 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Proportional Assist Ventilation</keyword>
  <keyword>Pressure Support Ventilation</keyword>
  <keyword>Weaning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

